Bicara Therapeutics (NASDAQ:BCAX) Shares Gap Down – Here’s Why

Bicara Therapeutics Inc. (NASDAQ:BCAX) shares gapped down before the market opened on Monday . The stock had previously closed at $12.42, but opened at $12.03. Bicara Therapeutics shares last traded at $12.21, with a volume of 12,488 shares trading hands.

Analyst Ratings Changes

Several equities research analysts recently weighed in on BCAX shares. Cantor Fitzgerald restated an “overweight” rating and set a $13.01 price target on shares of Bicara Therapeutics in a research report on Thursday. Wedbush restated an “outperform” rating and set a $31.00 price target on shares of Bicara Therapeutics in a research report on Wednesday, February 12th. Finally, HC Wainwright lifted their price target on Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, January 27th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $36.50.

Bicara Therapeutics Price Performance

The business has a fifty day simple moving average of $13.19.

Institutional Investors Weigh In On Bicara Therapeutics

Several hedge funds have recently added to or reduced their stakes in BCAX. Spire Wealth Management bought a new stake in Bicara Therapeutics in the fourth quarter worth $31,000. BNP Paribas Financial Markets bought a new stake in Bicara Therapeutics in the fourth quarter worth $32,000. Legal & General Group Plc bought a new stake in Bicara Therapeutics in the fourth quarter worth $33,000. Summit Investment Advisors Inc. bought a new stake in Bicara Therapeutics in the fourth quarter worth $35,000. Finally, Virtus ETF Advisers LLC bought a new stake in Bicara Therapeutics in the fourth quarter worth $69,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.